Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
ENANTA PHARMACEUTICALS INC (ENTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus ; Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million"
05/08/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19 • Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million • On Track to Report Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus, in June • Royalty Revenue for the Quarter was $17.8 Million"
02/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET • Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May • Expects Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus , in 2Q 2023 • Expands Robust Pipeline with New Research Programs Developing SARS-CoV-2 Papain-Like Protease Inhibitors and Human Metapneumovirus /RSV Dual-Inhibitors • Revenue for the Quarter was $23.6 Million"
11/21/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
11/22/2021 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET  Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022  Reported Positive Clinical Data from Two Phase 1b Studies of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic and NUC-Suppressed Chronic HBV Patients; Terminated Clinical Development of EDP-721, an Oral HBV RNA Destabilizer  Announced Decision to Pursue Combination Approaches with Farnesoid X Receptor Agonists for Non-Alcoholic Steatohepatitis Through an Out-Licensing Strategy  Royalty Revenue for the Quarter was $23...."
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
11/23/2020 8-K Quarterly results
Docs: "Evercore ISI 3rd Annual Virtual HealthCONx Conference, December 1 - 3, 2020 • 39 th Annual JP Morgan Virtual Healthcare Conference, January 11 - 14, 2021 • Enanta plans to issue its fiscal first quarter 2021 financial results press release, and hold a conference call regarding those results, on February 8, 2021. Conference Call and Webcast Information Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial 840-0595 in the U.S. or 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 23, 2020, through 11:59 p.m. ET on November 25, 2020 by dialing 859-2056 from the U.S. or 537-3406 for international callers. The passcode for bo..."
08/04/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/06/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Webcast and Conference Call Today at 4:30 p.m. ET"
11/21/2019 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET"
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019 Webcast and Conference Call today at 4:30 p.m. ET"
02/06/2019 8-K Quarterly results
11/26/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 26, 2018 ENANTA PHARMACEUTICALS, INC. Delaware 001-35839 04-3205099 500 Arsenal Street, Watertown, Massachusetts 02472 607-0800 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 und...",
"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Webcast and Conference Call today at 4:30 p.m. ET"
05/08/2018 8-K Quarterly results
Docs: "Media Contact Kari Watson MacDougall Biomedical Communications 781-235-3060 [email protected] ###"
02/07/2018 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017 Webcast and Conference Call today at 4:30 p.m. ET"
11/20/2017 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017 Webcast and Conference Call today at 4:30 p.m. ET"
08/07/2017 8-K Quarterly results
Docs: "Cash and marketable securities totaled $235.3 million at June 30, 2017 • Royalty revenue for the quarter was $7.5 million • Milestone payments totaling $65 million earned following AbbVie’s EU approval of MAVIRET™ in July, and U.S. approval of MAVYRET™ in August • RSV and NASH/PBC clinical programs continue to advance toward new stages next quarter WATERTOWN, Mass., August 7, 2017 – Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2017. Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $235.3 million at June 30, 2017. Th..."
05/09/2017 8-K/A Form 8-K/A - Current report [Amend]
05/08/2017 8-K Form 8-K - Current report
02/08/2017 8-K Form 8-K - Current report
11/21/2016 8-K Form 8-K - Current report
08/08/2016 8-K Form 8-K - Current report
05/09/2016 8-K Form 8-K - Current report
02/08/2016 8-K Form 8-K - Current report
11/23/2015 8-K Form 8-K - Current report
08/06/2015 8-K Form 8-K - Current report
05/07/2015 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy